title: Factors affecting membrane-controlled drug release for an osmotic pump tablet (OPT) utilizing (SBE)(7m)-beta-CD as both a solubilizer and osmotic agent.
abstract: OBJECTIVE
  The purpose of this study was to define membrane controlling factors responsible for drug release from a controlled-porosity osmotic pump tablet (OPT) that utilizes a sulfobutyl ether-beta-cyclodextrin, (SBE)(7m)-beta-CD, as both a solubilizing and osmotic agent.
  
  
  METHODS
  The OPT was spray coated with cellulose acetate solutions varying the amount and size of micronized lactose, the amount of triethyl citrate (TEC) and the composition ratio of dichlormethane to ethanol. Chlorpromazine (CLP) was used as a model drug. The release of CLP from the OPTs was studied using the Japanese Pharmacopoeia dissolution method. The membrane surface area of the OPTs were measured with multi-point analysis by the gas absorption method.
  
  
  RESULTS
  The release rate of CLP from OPTs containing (SBE)(7m)-beta-CD increased with increasing amounts of micronized lactose and decreasing amounts of TEC and lactose particle size in the membrane. Also, the CLP release rates from the spray-coated OPTs using mixtures of varying ratios of dichlormethane to ethanol were almost identical. The membrane surface area of the OPTs following release of membrane components had a linear relationship to CLP release rates from the OPTs.
  
  
  CONCLUSIONS
  The present results confirmed that the membrane controlling factors responsible for the drug release were the amount and size of micronized lactose and the amount of TEC in the membrane.
authors.affiliation: Technological Development Laboratories, Fujisawa Pharmaceutical Co., Ltd., 1-6, Kashima 2-chome, Yodogawa-ku, Osaka 532-8514, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Okimoto
authors.forename: A
authors.initials: A
authors.lastname: Ohike
authors.forename: R
authors.initials: R
authors.lastname: Ibuki
authors.forename: O
authors.initials: O
authors.lastname: Aoki
authors.forename: N
authors.initials: N
authors.lastname: Ohnishi
authors.forename: R A
authors.initials: RA
authors.lastname: Rajewski
authors.forename: V J
authors.initials: VJ
authors.lastname: Stella
authors.forename: T
authors.initials: T
authors.lastname: Irie
authors.forename: K
authors.initials: K
authors.lastname: Uekama
mesh_terms: D014150:Antipsychotic Agents / Q000493:pharmacokinetics; D002746:Chlorpromazine / Q000493:pharmacokinetics*; D003505:Cyclodextrins / Q000737:chemistry*; D003692:Delayed-Action Preparations / Q000737:chemistry*; D066298:In Vitro Techniques; D008567:Membranes, Artificial; D008855:Microscopy, Electron, Scanning; D009995:Osmosis; D010316:Particle Size; D012995:Solubility; D013607:Tablets; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D003505:Cyclodextrins; D003692:Delayed-Action Preparations; D008567:Membranes, Artificial; D013607:Tablets; D002746:Chlorpromazine